Strategic Swiss Partners AG Appoints Prof. Mike Chan as Honorary President of Regenerative Medicine

ZÜRICH, Switzerland, May 1, 2025 — Strategic Swiss Partners (SSP), a Zurich-based firm, has appointed Prof. Dato’ Sri Dr. Mike Chan as its Honorary President of Regenerative Medicine.

Prof. Chan brings extensive expertise in regenerative medicine, serving as the Asian Chairman and Head of the Scientific Committee for Regenerative Medicine at the European Society of Preventive, Regenerative, and Anti-Aging Medicine (ESAAM). He also holds positions as Associate Professor at the American Academy of Stem Cell Physicians (AASCP) and Chairman of Japan’s Medical Association for Regenerative Medicine, MMJ.

In his role at SSP, Prof. Chan will provide strategic guidance in regenerative medicine, leveraging his global experience to enhance the firm’s healthcare advisory services.

“We are honored to welcome Prof. Chan to this important position,” said Guna R. Mahalingam, CEO & Founder of Strategic Swiss Partners. “His insights and vision are invaluable to our global mission in advancing healthcare innovation.”

Guna R. Mahalingam, brings extensive experience in international business development and cross-border collaborations to the firm’s leadership. He is also the Malaysian Honorary Consul for the Consulate of Malaysia in Zurich, Switzerland, Mr. Mahalingam serves as a vital diplomatic bridge between the two nations, fostering economic, cultural, and scientific exchanges. His dual roles in business and diplomacy have positioned him uniquely to advance global partnerships in healthcare innovation and life sciences, with a particular focus on creating sustainable connections between European expertise and Asian markets. Under his guidance, SSP has emerged as a significant facilitator of international cooperation in regenerative medicine and future-oriented industries.

Currently based at the European Wellness Center in Lugano, Switzerland, Prof. Chan founded the European Wellness Biomedical Group and has led major advancements in precursor stem cell-based therapeutics. His reputation as a thought leader is supported by numerous international collaborations, keynote lectures, and published research on age reversal, neurodegeneration, and immuno-rejuvenation.

“It is an honor to accept this appointment,” said Prof. Chan. “I believe regenerative medicine holds the key to redefining healthcare—and through this partnership, we will build bridges across research, practice, and policy to make that vision a reality.”

Strategic Swiss Partners is a leading management and financial advisory firm dedicated to advancing cross-border collaborations in health sciences, life sciences, and future-oriented industries. Headquartered in Switzerland with offices in China, the UAE, and Malaysia, SSP provides consulting services to Fortune 500 companies and offers specialized investment solutions across various industries. The appointment of Prof. Chan as Honorary President of Regenerative Medicine represents an important step in the firm’s evolution as it expands its footprint in personalized and precision medicine, further strengthening its position as a global advisor in healthcare innovation and strategic development.